💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Brigatinib

CHEMBL3545311 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
584.1 g/mol
LogP
4.6
Phase
4

A next-generation ALK inhibitor used to treat non-small cell lung cancer in patients whose tumors have an ALK gene rearrangement, particularly those who have progressed on other ALK inhibitors. It is designed to overcome resistance mechanisms and penetrate the brain, where lung cancer frequently spreads. It is taken orally once daily.

الوزن الجزيئي

584,1000 g/mol

LogP

4,60

TPSA

85,90 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer

آلية العمل

Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1

                

                

                
                

                    
InChI

                    
InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)

                

                

                

                    
                    

                        
Molecular Formula

                        
C29H39ClN7O2P

                    

                    
                    

                        
HBD / HBA

                        
2 / 9

                    

                    
                    

                        
الروابط القابلة للدوران

                        
8

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
40

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
A next-generation ALK inhibitor used to treat non-small cell lung cancer in patients whose tumors have an ALK gene rearrangement, particularly those who have progressed on other ALK inhibitors. It is designed to overcome resistance mechanisms and penetrate the brain, where lung cancer frequently spreads. It is taken orally once daily.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Brigatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3545311.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 68165256.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.